Gates Package — page 245

Members of the Accelerating COVID-19 Therapeutic Interventions and Vaccines (ACTIV) Partnership Bill & Melinda Gates Foundation Emilio Emini, Ph.D. Director, TB & HIV Program Bill & Melinda Gates Foundation Emily Erbelding, M.D., M.P.H. Director, Division of Microbiology and Infectious Diseases National Institute of Allergy and Infectious Diseases, NIH Stan Erck, M.B.A. President and Chief Executive Officer Novavax Anthony Fauci, M.D. Director, National Institute of Allergy and Infectious Diseases NIH Gary Gibbons, M.D. Director, National Heart, Lung, and Blood Institute NIH Penny Heaton, Ph.D. Chief Executive Officer Bill & Melinda Gates Medical Research Institute Tom Hudson, M.D. Senior Vice President, R&D; Chief Scientific Officer AbbVie Eric Hughes, M.D., Ph.D. Global Development Unit Head, Immunology, Hepatology & Dermatology and China Region Development Head Novartis Kathrin Jansen, Ph.D. Senior Vice President and Head of Vaccine Research and Development Pfizer Robert Johnson, PhD. Director, Division of Influenza and Emerging Infectious Diseases Biomedical Advanced Research and Development Authority Lynn Kramer, M.D. Vice President, Chief Clinical Officer, Neurology Business Group Eisai Michael Kurilla, M.D., Ph.D.